Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies

Mohamed Elmeliegy, Hoi Kei Lon, Diane Wang, Wei An Ma, Lindsay King, Andrea Viqueira, Akos Czibere

Blood (2023) 142 (Supplement 1): 3345.

https://doi.org/10.1182/blood-2023-190341

Published: 2023

Journal Articles

Elranatamab Exposure-Efficacy Analysis in Patients with Relapsed or Refractory Multiple Myeloma: Insights from Pooled Magnetismm Studies

Hoi Kei Lon, Jennifer Hibma, Jason Williams, Diane Wang, David Gifondorwa, Wei An Ma, Lindsay King, Umberto Conte, Akos Czibere, Mohamed Elmeliegy

Blood (2023) 142 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2023-190102

Published: 2023

Journal Articles

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Sheena Sharma, Diane Wang, Hoi-Kei Lon, Pooneh Soltantabar, Andrea Viqueira, Akos Czibere, Anne Hickman, Jane Liang White, Mohamed Elmeliegy

Blood (2022) 140 (Supplement 1): 10036–10038.

https://doi.org/10.1182/blood-2022-169836

Published: 2022

Journal Articles

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Anne Hickman, Jennifer Hibma, Hoi-Kei Lon, Joseph Piscitelli, Pooneh Soltantabar, Diane Wang, Sibo Jiang, Gregory Finn, Akos Czibere

Blood (2022) 140 (Supplement 1): 7174–7175.

https://doi.org/10.1182/blood-2022-169971

Published: 2022

Journal Articles

Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-140776

Published: 2020

Journal Articles

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Fabian Zohren, Ingmar Bruns, Sabrina Pechtel, Thomas Schroeder, Roland Fenk, Akos Czibere, Georg Maschmeyer, Dorothea Kofahl-Krause, Norbert Niederle, Gerhard Heil, Christoph Losem, Manfred Welslau, Wolfram Brugger, Ulrich Germing, Ralf Kronenwett, Juergen Barth, Mathias J. Rummel, Rainer Haas, Guido Kobbe

Blood (2015) 126 (12): 1407–1414.

https://doi.org/10.1182/blood-2015-03-630012

Published: 2015

Includes: Supplemental data

Journal Articles

C/EBPα is required for development of dendritic cell progenitors

Robert S. Welner, Deepak Bararia, Giovanni Amabile, Akos Czibere, Touati Benoukraf, Christian Bach, K. Disnika Senali Abayratna Wansa, Min Ye, Hong Zhang, Tadafumi Iino, Christopher J. Hetherington, Koichi Akashi, Daniel G. Tenen

Blood (2013) 121 (20): 4073–4081.

https://doi.org/10.1182/blood-2012-10-463448

Published: 2013

Includes: Supplemental data

Journal Articles

Multiple myeloma–related deregulation of bone marrow–derived CD34 + hematopoietic stem and progenitor cells

Blood (2012) 120 (13): 2620–2630.

https://doi.org/10.1182/blood-2011-04-347484

Published: 2012

Includes: Supplemental data

Journal Articles

Phase II Study of Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) As First Salvage Therapy in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT): Final Results From the AZARELA-Trial (NCT-00795548)

Thomas Schroeder, MD, Akos Czibere, MD, PhD, Nicolaus Kröger, Uwe Platzbecker, MD, Gesine Bug, Lutz Uharek, Prof., Dr., Thomas Luft, Christine Wolschke, Ingmar Bruns, MD, Fabian Zohren, MD, Roland Fenk, Rainer Haas, MD, Prof, Guido Kobbe, MD

Blood (2011) 118 (21): 656.

https://doi.org/10.1182/blood.V118.21.656.656

Published: 2011

Journal Articles

The Disease-Related Bone Marrow Microenvironment Alters Hematopoietic Stem and Progenitor Function in Multiple Myeloma Patients

Ingmar Bruns, MD, Ron-Patrick Cadeddu, Ines Brückmann, Sebastian Buest, Julia Fröbel, Thomas Schroeder, Stefanie Geyh, Ali-Nuri Hünerlitürkoglu, Guido Kobbe, MD, Roland Fenk, Andreas Trumpp, Akos Czibere, MD, PhD, Rainer Haas

Blood (2011) 118 (21): 2898.

https://doi.org/10.1182/blood.V118.21.2898.2898

Published: 2011

Journal Articles

Imatinib Induced Molecular Response in CD34+ Hematopoietic Stem and Progenitor Cells of Patients with Chronic Myeloid Leukemia Following the First Week of Therapy

Daniela Bruennert, Akos Czibere, MD, PhD, Ingmar Bruns, MD, PhD, Sabrina Pechtel, Norbert Gattermann, MD, Ralf Kronenwett, Rainer Haas, Neumann Frank

Blood (2008) 112 (11): 3231.

https://doi.org/10.1182/blood.V112.11.3231.3231

Published: 2008

Journal Articles

Hematopoiesis in Chronic Phase CML emerges from Hematopoietic Stem Cells with a Transcriptional Phenotype Resembling Normal Myeloid Progenitor Cells.

Ingmar Bruns, MD, PhD, Akos Czibere, MD, PhD, Patrick Cadeddu, Frederik Roels, Johannes C Fischer, Sebastian Büst, Daniela Brünnert, Ulrich Steidl, MD, PhD, Benedict Brors, Norbert Gattermann, MD, Ralf Kronenwett, Rainer Haas

Blood (2008) 112 (11): 3365.

https://doi.org/10.1182/blood.V112.11.3365.3365

Published: 2008

Journal Articles

The Neuropeptides Orexin a and B Have An Impact on Functional Properties of Human CD34+ Stem and Progenitor Cells.

Ingmar Bruns, MD, PhD, Patrick Cadeddu, Sebastian Büst, Boris Goerg, Johannes C Fischer, Oliver Selbach, Ulrich Steidl, MD, PhD, Ralf Kronenwett, Rainer Haas, Guido Kobbe, Akos Czibere, MD, PhD

Blood (2008) 112 (11): 1393.

https://doi.org/10.1182/blood.V112.11.1393.1393

Published: 2008

Journal Articles

Ap-1 Family Members C-Jun, JunB and Fra-2 Mediate Apoptosis and Differentiation in AML through Activation of GADD45á and ADFP Following Non-Steroidal Anti-Inflammatory Drug Treatment.

Akos Czibere, MD, PhD, Raminder Singh, PhD, Ingmar Bruns, MD, PhD, Luiz Fernando Zerbini, PhD, Rainer Haas

Blood (2008) 112 (11): 1196.

https://doi.org/10.1182/blood.V112.11.1196.1196

Published: 2008

Journal Articles

Molecular Level of Minimal Residual Disease in Bone Marrow Before High-Dose Therapy and Autologous Stem Cell Transplantation Is a Prognostic Parameter in Patients with Multiple Myeloma.

Roland Fenk, MD, Mark Korthals, Nina Sehnke, Ingmar Bruns, MD, Akos Czibere, MD, Fabian Zohren, Nancy Safaian, Ariane Dienst, Leilani Ruf, MD, Frank Neumann, MD, Rainer Haas, MD, Ralf Kronenwett, MD, Guido Kobbe, MD

Blood (2007) 110 (11): 1496.

https://doi.org/10.1182/blood.V110.11.1496.1496

Published: 2007

Journal Articles

Treatment with Natalizumab in Patients with Multiple Sclerosis Is Associated with Increased Numbers of Circulating CD34+ Cells in the Peripheral Blood.

Fabian Zohren, MD, Akos Czibere, MD, Diamandis Toutzaris, MD, Hans-Peter Hartung, MD, Ingmar Bruns, MD, Rainer Haas, MD

Blood (2007) 110 (11): 4916.

https://doi.org/10.1182/blood.V110.11.4916.4916

Published: 2007

Journal Articles

Fludarabine, Amsacrine, High-Dose Cytarabine and Total Body Irridation Followed by Allogeneic Stem Cell Transplantation for the Treatment of High Risk or Relapsed Acute Lymphoblastic Leukemia.

Fabian Zohren, MD, Thorsten Graef, MD, Ingmar Bruns, MD, Akos Czibere, MD, Fenk Roland, MD, Haas Rainer, MD, Kobbe Guido

Blood (2007) 110 (11): 5086.

https://doi.org/10.1182/blood.V110.11.5086.5086

Published: 2007

Journal Articles

Sequential Induction Chemotherapy, and Early Intensified Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Myeloid Leukemia.

Thorsten Graef, MD, Nikola Schmittner, Frank Neumann, MD, Roland Fenk, MD, Fabian Zohren, MD, Akos Czibere, MD, Norbert Gattermann, MD, Rainer Haas, MD, Guido Kobbe, MD

Blood (2006) 108 (11): 5367.

https://doi.org/10.1182/blood.V108.11.5367.5367

Published: 2006

Journal Articles

5-Azacitidine in Combination with Donor Lymphocyte Infusions for the Treatment of Patients with MDS or AML Relapsing after Allogeneic Stem Cell Transplantation.

Akos Czibere, MD, Thorsten Graef, MD, Jens Lind, Norbert Gattermann, MD, Fabian Zohren, MD, Roland Fenk, MD, Rainer Haas, MD, Guido Kobbe, MD

Blood (2006) 108 (11): 5341.

https://doi.org/10.1182/blood.V108.11.5341.5341

Published: 2006

Journal Articles

A Transcriptional Signature Distinguishing Short and Long-Term Surviving Patients with MDS.

Akos Czibere, MD, Christian Prall, MD, Ulrich Steidl, MD, PhD, Ingmar Bruns, MD, Andrea Kuendgen, MD, Aristoteles Giagounidis, MD, Rainer Haas, MD, Guido Kobbe, MD, Ulrich Germing, MD, Manuel Aivado, MD

Blood (2006) 108 (11): 4866.

https://doi.org/10.1182/blood.V108.11.4866.4866

Published: 2006

NARROW

Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies

Elranatamab Exposure-Efficacy Analysis in Patients with Relapsed or Refractory Multiple Myeloma: Insights from Pooled Magnetismm Studies

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

C/EBPα is required for development of dendritic cell progenitors

Multiple myeloma–related deregulation of bone marrow–derived CD34 + hematopoietic stem and progenitor cells

The Disease-Related Bone Marrow Microenvironment Alters Hematopoietic Stem and Progenitor Function in Multiple Myeloma Patients

Imatinib Induced Molecular Response in CD34+ Hematopoietic Stem and Progenitor Cells of Patients with Chronic Myeloid Leukemia Following the First Week of Therapy

Hematopoiesis in Chronic Phase CML emerges from Hematopoietic Stem Cells with a Transcriptional Phenotype Resembling Normal Myeloid Progenitor Cells.

The Neuropeptides Orexin a and B Have An Impact on Functional Properties of Human CD34+ Stem and Progenitor Cells.

Ap-1 Family Members C-Jun, JunB and Fra-2 Mediate Apoptosis and Differentiation in AML through Activation of GADD45á and ADFP Following Non-Steroidal Anti-Inflammatory Drug Treatment.

Molecular Level of Minimal Residual Disease in Bone Marrow Before High-Dose Therapy and Autologous Stem Cell Transplantation Is a Prognostic Parameter in Patients with Multiple Myeloma.

Treatment with Natalizumab in Patients with Multiple Sclerosis Is Associated with Increased Numbers of Circulating CD34+ Cells in the Peripheral Blood.

Fludarabine, Amsacrine, High-Dose Cytarabine and Total Body Irridation Followed by Allogeneic Stem Cell Transplantation for the Treatment of High Risk or Relapsed Acute Lymphoblastic Leukemia.

Sequential Induction Chemotherapy, and Early Intensified Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Myeloid Leukemia.

5-Azacitidine in Combination with Donor Lymphocyte Infusions for the Treatment of Patients with MDS or AML Relapsing after Allogeneic Stem Cell Transplantation.

A Transcriptional Signature Distinguishing Short and Long-Term Surviving Patients with MDS.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only